Payment overview · 2025
General Payments
$967.37
53 reported records · 14 companies
Healthcare provider profile · identity verified
Shawn Hall, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GONZALES, LA · NPI 1306844147
Verified facts
What the public records show
CMS Open Payments records show Shawn Hall, M.D. received $967.37 in general payments during 2025 across 53 reported records.
GlaxoSmithKline, LLC. accounted for 23.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 95 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Myrbetriq by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 217 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 254 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 224 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $222.76 | 23.0% | 12 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $198.14 | 20.5% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $174.48 | 18.0% | 13 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $73.62 | 7.6% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $54.36 | 5.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.33 | 4.9% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.97 | 4.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.14 | 3.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.00 | 3.2% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.40 | 2.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.85 | 2.0% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $19.74 | 2.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.93 | 1.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.65 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $967.37 | 53 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $198.14 | 9 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $165.43 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.45 | 8 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $77.13 | 4 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $73.62 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $72.03 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $58.30 | 5 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $57.33 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $45.97 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.50 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.00 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $27.77 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.40 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $19.85 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $19.74 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 217 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 254 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
30 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
95 | 20 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
65 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
217 | 41 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
254 | 43 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
224 | 46 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 20 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 920 | 204 |
| Alprazolam | Alprazolam | 874 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 846 | 217 |
| Pravastatin Sodium | Pravastatin Sodium | 769 | 197 |
| Amlodipine Besylate | Amlodipine Besylate | 680 | 170 |
| Gabapentin | Gabapentin | 564 | 125 |
| Pantoprazole Sodium | Pantoprazole Sodium | 494 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 109 |
| Metformin Hcl Er | Metformin Hcl | 386 | 109 |
| Escitalopram Oxalate | Escitalopram Oxalate | 359 | 77 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 334 | 70 |
| Lisinopril | Lisinopril | 318 | 88 |
| Zolpidem Tartrate | Zolpidem Tartrate | 300 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 291 | 86 |
| Omeprazole | Omeprazole | 289 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 71 |
| Sertraline Hcl | Sertraline Hcl | 275 | 70 |
| Mounjaro | Tirzepatide | 254 | 43 |
| Losartan Potassium | Losartan Potassium | 251 | 67 |
| Trazodone Hcl | Trazodone Hcl | 250 | 53 |
| Ezetimibe | Ezetimibe | 228 | 69 |
| Ozempic | Semaglutide | 224 | 46 |
| Jardiance | Empagliflozin | 217 | 41 |
| Metformin Hcl | Metformin Hcl | 209 | 55 |
| Celecoxib | Celecoxib | 191 | 44 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 37 |
| Furosemide | Furosemide | 191 | 58 |
| Tramadol Hcl | Tramadol Hcl | 180 | 44 |
| Clonazepam | Clonazepam | 178 | 28 |
| Simvastatin | Simvastatin | 175 | 45 |
| Montelukast Sodium | Montelukast Sodium | 161 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 142 | 39 |
| Citalopram Hbr | Citalopram Hydrobromide | 139 | 33 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 136 | 26 |
| Alendronate Sodium | Alendronate Sodium | 134 | 37 |
| Lorazepam | Lorazepam | 133 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 131 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 127 | 44 |
| Meloxicam | Meloxicam | 127 | 42 |
| Glimepiride | Glimepiride | 126 | 31 |
| Allopurinol | Allopurinol | 121 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 41 |
| Buspirone Hcl | Buspirone Hcl | 115 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 114 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 112 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 110 | 24 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 109 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 105 | 27 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 103 | 23 |
| Bupropion Xl | Bupropion Hcl | 102 | 23 |
| Chlorthalidone | Chlorthalidone | 100 | 25 |
| Januvia | Sitagliptin Phosphate | 100 | 21 |
| Synthroid | Levothyroxine Sodium | 95 | 20 |
| Temazepam | Temazepam | 91 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 89 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 22 |
| Potassium Chloride | Potassium Chloride | 88 | 24 |
| Amitriptyline Hcl | Amitriptyline Hcl | 86 | 18 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 14 |
| Atenolol | Atenolol | 80 | 23 |
| Carvedilol | Carvedilol | 76 | 24 |
| Fenofibrate | Fenofibrate | 76 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 18 |
| Valsartan | Valsartan | 75 | 22 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 71 | 19 |
| Eliquis | Apixaban | 70 | 20 |
| Irbesartan | Irbesartan | 68 | 15 |
| Oxycodone Hcl | Oxycodone Hcl | 68 | suppressed |
| Pregabalin | Pregabalin | 68 | 15 |
| Lovastatin | Lovastatin | 66 | 19 |
| Diazepam | Diazepam | 65 | 16 |
| Estradiol | Estradiol | 65 | 21 |
| Myrbetriq | Mirabegron | 65 | 13 |
| Fluconazole | Fluconazole | 57 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 56 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 53 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 53 | 25 |
| Mirtazapine | Mirtazapine | 52 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 14 |
| Famotidine | Famotidine | 50 | 13 |
| Spironolactone | Spironolactone | 50 | 17 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 49 | 23 |
| Benazepril Hcl | Benazepril Hcl | 48 | 14 |
| Gemfibrozil | Gemfibrozil | 47 | suppressed |
| Baclofen | Baclofen | 46 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 45 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 42 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 34 |
| Ondansetron Odt | Ondansetron | 41 | 26 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 39 | 12 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 39 | 21 |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Methocarbamol | Methocarbamol | 36 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 35 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 35 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Amoxicillin | Amoxicillin | 33 | 29 |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | suppressed |
| Linzess | Linaclotide | 30 | 11 |
| Meclizine Hcl | Meclizine Hcl | 30 | 20 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Rybelsus | Semaglutide | 29 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 28 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Mupirocin | Mupirocin | 28 | 22 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Prednisone | Prednisone | 27 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 25 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | 11 |
| Cefdinir | Cefdinir | 24 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 23 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Verapamil Er | Verapamil Hcl | 24 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 23 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 23 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 22 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Nystatin | Nystatin | 21 | 17 |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Azithromycin | Azithromycin | 19 | 18 |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 18 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Premarin | Estrogens, Conjugated | 18 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 18 | suppressed |
| Trandolapril | Trandolapril | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Lacosamide | Lacosamide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Bystolic | Nebivolol Hcl | 12 | suppressed |
| Febuxostat | Febuxostat | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dotti | Estradiol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lidocaine | Lidocaine | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Np Thyroid | Thyroid,pork | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $967.37 · 53 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, Auvelity, COMIRNATY, FANAPT, FREESTYLE LIBRE 3, JARDIANCE, JOURNAVX, MOUNJARO, OTEZLA, PERCLOSE PROGLIDE, PREVNAR 20, QULIPTA, REPATHA, REXULTI, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error